Richard Stewart
2019
In 2019, Richard Stewart earned a total compensation of $796.6K as Chairman and Chief Executive Officer at OncoGenex Pharmaceuticals, a 27% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,500 |
|---|---|
| Option Awards | $109,144 |
| Salary | $500,000 |
| Total | $796,644 |
Stewart received $500K in salary, accounting for 63% of the total pay in 2019.
Stewart also received $187.5K in non-equity incentive plan and $109.1K in option awards.
Rankings
In 2019, Richard Stewart's compensation ranked 10,231st out of 13,971 executives tracked by ExecPay. In other words, Stewart earned more than 26.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,231 out of 13,971 | 27th |
Division Manufacturing | 4,142 out of 5,701 | 27th |
Major group Chemicals And Allied Products | 1,583 out of 2,200 | 28th |
Industry group Drugs | 1,356 out of 1,886 | 28th |
Industry In Vitro and In Vivo Diagnostic Substances | 43 out of 77 | 44th |
Source: SEC filing on April 2, 2020.
Stewart's colleagues
We found three more compensation records of executives who worked with Richard Stewart at OncoGenex Pharmaceuticals in 2019.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019